Nephros Stock (NASDAQ:NEPH)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$3.33

52W Range

$2.66 - $6.42

50D Avg

$3.24

200D Avg

$4.18

Market Cap

$36.26M

Avg Vol (3M)

$32.42K

Beta

1.50

Div Yield

-

NEPH Company Profile


Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.

Show More

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

31

IPO Date

Sep 21, 2004

Website

NEPH Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Other Revenue$24.00K$121.00K$97.00K
Royalty and Other Revenues$555.00K$127.00K-
Service$520.00K--
Royalty And Other Revenues--$128.00K

Fiscal year ends in Dec 25 | Currency in USD

NEPH Financial Summary


Dec 25Dec 24Dec 23
Revenue$18.79M$14.16M$14.24M
Operating Income$1.15M$6.00K$-1.59M
Net Income$1.19M$74.00K$-1.57M
EBITDA$1.32M$227.00K$-1.36M
Basic EPS$0.11$0.01$-0.15
Diluted EPS$0.11$0.01$-0.15

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26May 08, 26 | 12:00 AM
Q4 25Mar 12, 26 | 12:00 AM
Q3 25Nov 07, 25 | 4:30 PM

Peer Comparison


TickerCompany
OSTXOS Therapies Incorporated
OTLKOutlook Therapeutics, Inc.
SPRBSpruce Biosciences, Inc.
NRXPNRx Pharmaceuticals, Inc.
DXRDaxor Corporation
ICCCImmuCell Corporation
HOWLWerewolf Therapeutics, Inc.
ZJYLJin Medical International Ltd.
BEATHeartBeam, Inc.
ONMDOneMedNet Corporation